Phase I study dose escalation study for olaparib. 1 BRCA2-related castration-resistant prostate cancer patient was included in the study; he demonstrated significant, durable marker response as well as resolution of bone metastases. No responses in BRCA-mutation-negative cases. This evidence concerns the gene BRCA2 and prostate cancer.